Core Viewpoint - Enlivex Therapeutics Ltd. has denied false claims made by Tipranks.com regarding the suspension of its stock trading due to an internal investigation, asserting that the company continues to operate normally and its shares are trading regularly on both the Tel Aviv Stock Exchange and NASDAQ [1][2]. Company Operations - The company emphasizes that it is executing its operating plan and is optimistic about the potential of its product Allocetra™ to provide treatment solutions for osteoarthritis patients, who currently have limited options [3]. - Enlivex is a clinical-stage company focused on macrophage reprogramming immunotherapy, developing Allocetra™, which aims to reset non-homeostatic macrophages to their homeostatic state, crucial for immune system rebalancing [4]. Legal Actions - The CEO of Enlivex has stated that the company will pursue legal actions against those responsible for the false report, including the publishers and hosting service of Tipranks.com [3]. Investor Communication - The company urges investors to rely solely on official communications, including press releases and filings with the U.S. Securities and Exchange Commission, for accurate information [2].
Enlivex Issues Urgent Statement on Fraudulent News Dissemination